Caligan Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.72M | Sell |
638,908
-2,468,761
| -79% | -$22.1M | 1.1% | 13 |
|
|
2025
Q1 | $23.3M | Buy |
3,107,669
+111,737
| +4% | +$838K | 4.86% | 7 |
|
|
2024
Q4 | $22.5M | Buy |
2,995,932
+412,347
| +16% | +$3.1M | 5.71% | 6 |
|
|
2024
Q3 | $19.6M | Sell |
2,583,585
-2,015,152
| -44% | -$15.3M | 6.22% | 7 |
|
|
2024
Q2 | $28.4M | Buy |
4,598,737
+3,840,235
| +506% | +$23.7M | 6.64% | 5 |
|
|
2024
Q1 | $3.85M | Buy |
+758,502
| New | +$3.85M | 1.02% | 11 |
|